TY - JOUR
T1 - A long-term survival case of rectal cancer with virchow's lymph node metastasis by multimodality therapy
AU - Hirose, Hajime
AU - Ikeda, Masataka
AU - Miyoshi, Norikatsu
AU - Kim, Ho Min
AU - Okano, Miho
AU - Uemura, Mamoru
AU - Yamashita, Shinya
AU - Takemasa, Ichiro
AU - Mizushima, Tsunekazu
AU - Yamamoto, Hirofumi
AU - Ishii, Hideshi
AU - Sekimoto, Mitsugu
AU - Doki, Yuichiro
AU - Mori, Masaki
PY - 2010/11
Y1 - 2010/11
N2 - A 57-year-old man was diagnosed as having advanced rectal cancer that was suspected for a prostatic gland invasion. CPT-11 plus UFT/LV-based chemoradiotherapy (CRT) was administered. A total radiation dose was 50.4 Gy. After completion of CRT, rectal tumor has shrunken, but Virchow's lymph node metastasis was found on PET CT scan. Therefore, the main rectal tumor was resected first, and chemotherapy was then planned. After an abdominoperineal resection, mFOLF-0X6 was started. We have stopped mFOLFOX6 after 9 courses because of grade 3 peripheral neuropathy. FOLFIRI was administered thereafter for 27 courses until the confirmation of the shrinkage of the Virchow's lymph node. With a request from the patient, the chemotherapy was stopped for 7 months. Virchow's lymph node has re-grown. We restarted chemotherapy with FOLFOX+bevacizumab regimen. Although the re-grown Virchow's lymph node was unresectable, a tumor in the rectum was resected for a control of local symptom. We, then, introduced a sequential systemic chemotherapy. After that, we could continue the treatment for 38 months without spoiling the QOL. The patient is alive and come to see us as an outpatient.
AB - A 57-year-old man was diagnosed as having advanced rectal cancer that was suspected for a prostatic gland invasion. CPT-11 plus UFT/LV-based chemoradiotherapy (CRT) was administered. A total radiation dose was 50.4 Gy. After completion of CRT, rectal tumor has shrunken, but Virchow's lymph node metastasis was found on PET CT scan. Therefore, the main rectal tumor was resected first, and chemotherapy was then planned. After an abdominoperineal resection, mFOLF-0X6 was started. We have stopped mFOLFOX6 after 9 courses because of grade 3 peripheral neuropathy. FOLFIRI was administered thereafter for 27 courses until the confirmation of the shrinkage of the Virchow's lymph node. With a request from the patient, the chemotherapy was stopped for 7 months. Virchow's lymph node has re-grown. We restarted chemotherapy with FOLFOX+bevacizumab regimen. Although the re-grown Virchow's lymph node was unresectable, a tumor in the rectum was resected for a control of local symptom. We, then, introduced a sequential systemic chemotherapy. After that, we could continue the treatment for 38 months without spoiling the QOL. The patient is alive and come to see us as an outpatient.
UR - http://www.scopus.com/inward/record.url?scp=84866610439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866610439&partnerID=8YFLogxK
M3 - Article
C2 - 21224634
AN - SCOPUS:84866610439
SN - 0385-0684
VL - 37
SP - 2545
EP - 2547
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 12
ER -